Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report
| Autor: | Lars Hagmeyer, Winfried Randerath, Christina Priegnitz, Marcel Treml |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Vital capacity Indoles Pyridones Vital Capacity Antineoplastic Agents Gastroenterology 03 medical and health sciences Idiopathic pulmonary fibrosis chemistry.chemical_compound 0302 clinical medicine Pharmacotherapy Internal medicine Concomitant Therapy Humans Medicine 030212 general & internal medicine Lung function business.industry Anti-Inflammatory Agents Non-Steroidal Pirfenidone medicine.disease Idiopathic Pulmonary Fibrosis Surgery 030228 respiratory system chemistry Concomitant Drug Therapy Combination Nintedanib business medicine.drug |
| Zdroj: | Respiration. 91:327-332 |
| ISSN: | 1423-0356 0025-7931 |
| Popis: | Pirfenidone and nintedanib are both pleiotropic anti-fibrotic agents approved for the treatment of idiopathic pulmonary fibrosis (IPF) as monotherapy. To date, evidence supporting their efficacy as concomitant therapy has not been reported. Here, we present the first case of a Caucasian male patient with IPF treated with both pirfenidone and nintedanib following 2 years of treatment with pirfenidone monotherapy. Over a 24-month period, there was a clear decline in the patient's forced vital capacity from 3.5 liter before initiation of treatment to 2.5 liter after 24 months. Concomitant nintedanib treatment was initiated in March 2015. Lung function stabilized, and the two treatments were well tolerated. Treatment with pirfenidone and nintedanib has currently been ongoing for nearly 12 months. This is the first report of a successful long-term treatment with pirfenidone and nintedanib and suggests that in selected cases, concomitant anti-fibrotic therapy may represent a safe and therapeutically valuable escalation option after pirfenidone monotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|